A clinical study of CA-50 as a tumour marker for monitoring of colorectal cancer

Med Oncol Tumor Pharmacother. 1988;5(3):165-71. doi: 10.1007/BF02986440.

Abstract

Using a radioimmunoassay we have determined serum levels of the carcinoma-associated antigen CA-50 in 266 patients with colorectal cancer. Elevated CA-50 levels were found in Dukes' A (15%), Dukes' B (43%), Dukes' C (31%) and Dukes' D (65%). Patients who had developed a recurrence had 66% elevated levels. 25% of resected patients with no evidence of disease also had elevated CA-50 levels. From 139 patients operated on for a Dukes' A-C, a rise in CA-50 levels from the pre- to the 6-9 month post-operative sample was demonstrated in 12 cases in the absence of any clinical evidence for a recurrence. On follow-up, a recurrence later developed in all these cases with lead times of CA-50 titre rises ranging from 5 to 40 months. A rise in CA-50 levels after resection of a Dukes' A-C is indicative of a recurrence and may precede any clinical evidence of disease by several months or years. Data is also presented from 552 cases with colorectal cancer analysed with a immunoradiometric assay.

Publication types

  • Comparative Study

MeSH terms

  • Antigens, Neoplasm / analysis*
  • Antigens, Tumor-Associated, Carbohydrate
  • Biomarkers, Tumor / blood*
  • Colonic Neoplasms / immunology*
  • Colonic Neoplasms / pathology
  • Colonic Neoplasms / surgery
  • Follow-Up Studies
  • Humans
  • Neoplasm Recurrence, Local / blood
  • Neoplasm Recurrence, Local / diagnosis
  • Neoplasm Staging
  • Postoperative Care / methods
  • Predictive Value of Tests
  • Radioimmunoassay / methods
  • Rectal Neoplasms / immunology*
  • Rectal Neoplasms / pathology
  • Rectal Neoplasms / surgery

Substances

  • Antigens, Neoplasm
  • Antigens, Tumor-Associated, Carbohydrate
  • Biomarkers, Tumor